Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
暂无分享,去创建一个
Tomohiko Ichikawa | Koji Okihara | Hiromi Kumon | Hideaki Miyake | Masato Fujisawa | Tadashi Matsuda | Tsuneharu Miki | T. Matsuda | H. Miyake | T. Miki | K. Okihara | M. Fujisawa | H. Kumon | T. Ichikawa | Hiroyoshi Suzuki | Hiroyoshi Suzuki | Tetsurou Matsumoto | Tetsuro Matsumoto | Susumu Miyoshi | Motohiro Fujii | Yoshio Takihana | Tsuguru Usui | Seiichiro Ozono | S. Ozono | M. Fujii | Y. Takihana | T. Usui | S. Miyoshi
[1] G. Bubley,et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.
[2] E. Small,et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Hideo Araki,et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.
[4] G. Bubley,et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.
[5] A. D'Amico,et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Klotz. Combined androgen blockade in prostate cancer: meta‐analyses and associated issues , 2001, BJU international.
[7] T. Matsuda,et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. , 2004, Japanese journal of clinical oncology.
[8] L. Nazareth,et al. Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.
[9] K. Akakura,et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. , 2004, The Journal of urology.
[10] T. Tammela,et al. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. , 2000, The Journal of urology.
[11] K-H. Kurth. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials: Prostate Cancer Trialists Collaborative Group , 2000 .
[12] H. Miyake,et al. Clinical outcome of maximum androgen blockade using flutamide as second‐line hormonal therapy for hormone‐refractory prostate cancer , 2005, BJU international.
[13] Thomas J. Smith,et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Kota Takahashi,et al. The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate Cancer , 2004, Clinical Cancer Research.
[15] Crawford,et al. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.
[16] H. Scher,et al. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. , 1996, Urology.
[17] J. Lam,et al. Secondary hormonal therapy for advanced prostate cancer. , 2006, The Journal of urology.
[18] H. Scher,et al. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. , 1993, The Journal of urology.
[19] H. Scher,et al. Hormone-refractory (D3) prostate cancer: refining the concept. , 1995, Urology.
[20] H. Ito,et al. Androgen receptor involvement in the progression of prostate cancer. , 2003, Endocrine-related cancer.